Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
ADMA is in the long-term down -58% below S&P in 8 years.
Description: ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.7||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0.2%||Sales Growth - Q/Q||0.94%||P/E||-1.79|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-42.78%||ROE||-108.07%||ROI||-50.92%|
|Current Ratio||8.18||Quick Ratio||7.67||Long Term Debt/Equity||0.55||Debt Ratio||0.28|
|Gross Margin||37.25%||Operating Margin||-231.07%||Net Profit Margin||-247.78%||Dividend Payout Ratio|
|Cash From Financing Activities||10.46 M||Cash From Investing Activities||-6.87 M||Cash From Operating Activities||-4.22 M||Gross Profit||590 K|
|Net Profit||-3.61 M||Operating Profit||-3.2 M||Total Assets||33.93 M||Total Current Assets||30.98 M|
|Total Current Liabilities||3.79 M||Total Debt||15.09 M||Total Liabilities||20.5 M||Total Revenue||1.5 M|
|High 52 week||5.44||Low 52 week||2.06||Last close||5.44||Last change||0.37%|
|RSI||64.6||Average true range||0.32||Beta||0.52||Volume||94.85 K|
|Simple moving average 20 days||8.6%||Simple moving average 50 days||10.55%||Simple moving average 200 days||49.85%|
|Performance Week||9.02%||Performance Month||12.86%||Performance Quart||39.85%||Performance Half||77.78%|
|Performance Year||41.3%||Performance Year-to-date||69.47%||Volatility daily||2.91%||Volatility weekly||6.5%|
|Volatility monthly||13.33%||Volatility yearly||46.17%||Relative Volume||814.37%||Average Volume||124.83 K|
|New High||New Low|
2020-06-01 09:44:01 | Are Options Traders Betting on a Big Move in ADMA Biologics ADMA Stock?
2020-05-27 07:00:10 | ADMA Biologics to Participate in Jefferies Virtual Healthcare Conference
2020-05-21 07:00:10 | ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients
2020-05-07 10:30:42 | ADMA Biologics Inc ADMA Q1 2020 Earnings Call Transcript
2020-05-07 10:22:08 | Edited Transcript of ADMA earnings conference call or presentation 6-May-20 8:30pm GMT
2020-05-06 20:15:12 | Adma Biologics ADMA Reports Q1 Loss, Misses Revenue Estimates
2020-05-01 06:13:58 | Investors Who Bought ADMA Biologics NASDAQ:ADMA Shares Five Years Ago Are Now Down 60%
2020-04-29 07:00:10 | ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020
2020-03-13 01:16:42 | Edited Transcript of ADMA earnings conference call or presentation 12-Mar-20 8:30pm GMT
2020-03-12 14:30:00 | ADMA Biologics, Inc. to Host Earnings Call
2020-02-11 16:20:10 | ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
2020-02-06 16:06:44 | ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
2020-02-06 05:53:58 | When Will ADMA Biologics, Inc. NASDAQ:ADMA Become Profitable?
2019-12-23 05:36:41 | Have Insiders Been Buying ADMA Biologics, Inc. NASDAQ:ADMA Shares?
2019-12-17 07:08:10 | ADMA Biologics Added to NASDAQ Biotechnology Index
2019-12-14 20:04:31 | Hedge Funds Have Never Been More Bullish On ADMA Biologics Inc ADMA
2019-11-13 07:08:00 | ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference
2019-11-08 05:33:22 | Here's Why ADMA Biologics NASDAQ:ADMA Can Afford Some Debt
2019-11-04 07:08:00 | ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
2019-10-28 15:05:00 | Publicly traded biotechnology company to add 100 jobs in South Florida
2019-10-22 07:48:05 | ADMA Biologics Named Company of the Year by BioFlorida
2019-10-21 07:48:05 | ADMA Biologics Announces First Commercial Sales of ASCENIV™
2019-10-17 07:29:05 | ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy
2019-10-09 11:08:48 | Should You Worry About ADMA Biologics, Inc.'s NASDAQ:ADMA CEO Salary Level?
2019-10-07 07:08:00 | ADMA Biologics Announces Data Presented at IDWeek 2019
2019-10-03 07:08:00 | ADMA Biologics Announces Poster Presentation at IDWeek 2019
2019-09-23 07:08:00 | ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
2019-09-09 14:54:50 | What Kind Of Investor Owns Most Of ADMA Biologics, Inc. NASDAQ:ADMA?
2019-08-22 07:48:00 | ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®
2019-08-08 07:51:08 | Breakeven On The Horizon For ADMA Biologics, Inc. NASDAQ:ADMA
2019-08-08 07:08:00 | ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
2019-07-08 08:22:05 | ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
2019-06-27 09:30:13 | Did ADMA Biologics, Inc. NASDAQ:ADMA Insiders Buy Up More Shares?
2019-06-27 09:28:19 | How Many ADMA Biologics, Inc. NASDAQ:ADMA Shares Did Insiders Buy, In The Last Year?
2019-06-18 16:35:33 | ADMA Biologics: Selloff Creates Buying Opportunity